ReviewWorld journal of gastroenterology2025
Pancreatic cancer in 2025: Have we found a solution?
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.Molecular therapy. Oncology · 2026Article
- Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Comparative In Vitro Cytotoxicity ofCurrent issues in molecular biology · 2026Article
- High SOX17 expression is correlated with favorable prognosis and CD8(+) TILs expression in patients with pancreatic cancer after curative resection.Translational oncology · 2026Article
- VDR Activation Suppresses Pancreatic Cancer Metastasis Through Inhibition of the ERK Signaling Pathway.Cancers · 2026Article
- Evaluation of Pancreatic Lesions: Comparative Analysis of Endoscopic Ultrasonography, Computed Tomography, and Magnetic Resonance Imaging.Medicina (Kaunas, Lithuania) · 2026Article
- EASIX Score as an Independent Prognostic Marker in De Novo Metastatic Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is still one of the neoplasms with the worst prognosis. Late presentation at an unresectable or metastatic stage precluding surgery, aggressive biology, and resistance to antiblastic drugs make this disease a formidable foe. The authors, following the path already traced by the previous review, investigate and summarize the breakthroughs of recent years concerning this lethal disease. Areas of progress include improving prevention and early detection strategies, refining molecular understanding of pancreatic cancer, identifying more effective systemic therapies, and improving quality of life and surgical outcomes. No less important is the technological aspect that looks primarily at artificial intelligence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.